Items Tagged ‘amgen’

July 23rd, 2015

Blincyto® in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Appears Promising

By

Biotechnology company Amgen has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, amgen, blinatumomab, blincyto, Leukemia, News


October 10th, 2014

Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

By

THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia, all, amgen, blinatumomab, fda, Leukemia, News